252 related articles for article (PubMed ID: 15931645)
1. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
4. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function.
Hu KQ; Lee SM; Hu SX; Xia VW; Hillebrand DJ; Kyulo NL
Am J Gastroenterol; 2005 Sep; 100(9):2010-8. PubMed ID: 16128946
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters.
Bodlaj G; Berg J; Pichler R; Sailer T; Biesenbach G
J Nephrol; 2004; 17(1):112-7. PubMed ID: 15151267
[TBL] [Abstract][Full Text] [Related]
7. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
8. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the factor which has an influence on red blood cell deformability in patients with end-stage renal disease].
Tateishi K; Fujita J; Taminato T
Rinsho Byori; 2009 Oct; 57(10):965-70. PubMed ID: 19928493
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
11. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
12. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron supplementation in children on hemodialysis.
Leijn E; Monnens LA; Cornelissen EA
J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
[TBL] [Abstract][Full Text] [Related]
15. [Transferrin microheterogeneity in patients treated by maintenance haemodialysis].
Formanowicz D; Pietrzak I; Wiktorowicz K
Przegl Lek; 2007; 64(7-8):483-8. PubMed ID: 18409349
[TBL] [Abstract][Full Text] [Related]
16. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
[TBL] [Abstract][Full Text] [Related]
17. Oral mucosa symptoms, signs and lesions, in end stage renal disease and non-end stage renal disease diabetic patients.
de la Rosa García E; Mondragón Padilla A; Aranda Romo S; Bustamante Ramírez MA
Med Oral Patol Oral Cir Bucal; 2006 Nov; 11(6):E467-73. PubMed ID: 17072248
[TBL] [Abstract][Full Text] [Related]
18. Renal amyloidosis is associated with increased mortality in hemodialysis patients.
Sengul S; Arat Z; Ozdemir FN
Artif Organs; 2004 Sep; 28(9):846-52. PubMed ID: 15320948
[TBL] [Abstract][Full Text] [Related]
19. [Iron balance in hemodialysis in chronic uremia].
Kokot F; Warmuz A
Z Urol Nephrol; 1988 Apr; 81(4):263-8. PubMed ID: 3400353
[TBL] [Abstract][Full Text] [Related]
20. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron.
Prakash M; Upadhya S; Prabhu R
Clin Chim Acta; 2005 Oct; 360(1-2):194-8. PubMed ID: 15979061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
